Most Read Articles
Pearl Toh, 22 Jun 2017
The next-generation ALK inhibitor brigatinib yielded high and durable responses in both whole-body and intracranial endpoints, with a median progression-free survival (PFS) of over 1 year in patients with ALK-positive non-small cell lung cancer (NSCLC) whose disease had progressed after crizotinib, according to the ALTA* trial.
Jairia Dela Cruz, 21 Jun 2017
Control treatment with montelukast may effectively reduce acute exacerbations in preschool children with mild persistent asthma, according to a study from Japan.
Tristan Manalac, 27 Jun 2017
Prolonged sleep duration is an independent predictor of higher incident atrial fibrillation (AF) risks in a Chinese population, reports a new prospective, population-based study.
Rachel Soon, 01 Jun 2017

Pirfenidone, an oral antifibrotic and anti-inflammatory agent, is now indicated for the treatment of idiopathic pulmonary fibrosis (IPF) in Malaysia.

Adjuvant chemotherapy, cardiac disease history predict PCE after radiation for NSCLC

10 Sep 2017
Lack of public awareness about the way lung cancer strikes is a big factor in delaying diagnosis and treatment

Pericardial effusion (PCE) is a common adverse side effect following thoracic radiation therapy (RT) for locally-advanced nonsmall cell lung cancer (NSCLC), a new study reveals. Additionally, PCE risk is increased by adjuvant chemotherapy.

The effects of intensity-modulated radiation therapy (IMRT) vs passive scattering proton beam therapy for locally advanced, inoperable NSCLC were assessed in 201 patients (56.2 percent male). Those with chest irradiation or PCE prior to treatment were excluded.

The primary study endpoint was development of PCE. Other outcomes included time to development – calculated from the start of RT – and overall survival (OS). Univariate and Multivariate Cox proportional hazards analyses were used to determine hazard ratios (HR) for PCE development.

Over a median follow-up of 23.9 months, participants received a median RT dose of 74 Gy and heart dose of 12.2 Gy. PCE was reported in 42.8 percent (n=86) of the patients, of which 40.3 percent (n=81) had grade 2 and 5.2 percent (n=5) had grade 3 PCE.

The 1- and 2-year cumulative PCE incidence rates were 31.4 and 45.4 percent, respectively, with a median time to development of 8.9 months.

The OS at 2 years was significantly higher in the PCE group than in those without PCE (69.0 vs 44.3 percent; p=0.012); at 5 years, the difference in corresponding OS rates decreased (43.3 vs 25.6 percent).

In multivariate analysis, heart volume receiving 35 Gy >10 percent (HR, 2.14; p=0.002), adjuvant chemotherapy (HR, 2.82; p<0.001) and history of cardiac disease (HR, 1.68; p=0.020) were all independent risk predictors for PCE.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Pearl Toh, 22 Jun 2017
The next-generation ALK inhibitor brigatinib yielded high and durable responses in both whole-body and intracranial endpoints, with a median progression-free survival (PFS) of over 1 year in patients with ALK-positive non-small cell lung cancer (NSCLC) whose disease had progressed after crizotinib, according to the ALTA* trial.
Jairia Dela Cruz, 21 Jun 2017
Control treatment with montelukast may effectively reduce acute exacerbations in preschool children with mild persistent asthma, according to a study from Japan.
Tristan Manalac, 27 Jun 2017
Prolonged sleep duration is an independent predictor of higher incident atrial fibrillation (AF) risks in a Chinese population, reports a new prospective, population-based study.
Rachel Soon, 01 Jun 2017

Pirfenidone, an oral antifibrotic and anti-inflammatory agent, is now indicated for the treatment of idiopathic pulmonary fibrosis (IPF) in Malaysia.